Evidence map›Paper›PMID 28550609›Full record

ArticleJournal of general internal medicine2017

Validation of the TAPS-1: A Four-Item Screening Tool to Identify Unhealthy Substance Use in Primary Care.

Jan Gryczynski, Jennifer McNeely, Li-Tzy Wu, Geetha A Subramaniam, Dace S Svikis, Lauretta A Cathers, Gaurav Sharma, Jacqueline King, Eve Jelstrom, Courtney D Nordeck and 4 more

Registry-linked trialOpen access · bronzeAbstract readValidation Study
In one paragraph

Article in Journal of general internal medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05025787 (EN20-01), which is not on this map. Cited by 57 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 4 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05025787 phase2completednot on this mapstarted 2021, after this paper: background citation

EN20-01: A 24 Week Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Moderate to Severe Knee Osteoarthritis Pain.

TypeinterventionalSponsorMaurizio Fava, MDRan2021 to 2024Enrolled55ConditionsKnee OsteoarthritisArmsCNTX-6970, Placebo
3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 4 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Jan GryczynskiFriends Research Institute, 1040 Park Avenue, Suite 103, Baltimore, MD, 21201, USA. jgryczynski@friendsresearch.org.
Jennifer McNeelyNew York University School of Medicine, New York, NY, USA.
Li-Tzy WuDuke University School of Medicine, Durham, NC, USA.
Geetha A SubramaniamCenter for Clinical Trials Network, National Institute on Drug Abuse, North Bethesda, MD, USA.
Dace S SvikisVirginia Commonwealth University, Richmond, VA, USA.
Lauretta A CathersVirginia Commonwealth University, Richmond, VA, USA.
Gaurav SharmaEmmes Corporation, Rockville, MD, USA.
Jacqueline KingEmmes Corporation, Rockville, MD, USA.
Eve JelstromEmmes Corporation, Rockville, MD, USA.
Courtney D NordeckFriends Research Institute, 1040 Park Avenue, Suite 103, Baltimore, MD, 21201, USA.
Anjalee SharmaFriends Research Institute, 1040 Park Avenue, Suite 103, Baltimore, MD, 21201, USA.
Shannon G MitchellFriends Research Institute, 1040 Park Avenue, Suite 103, Baltimore, MD, 21201, USA.
Kevin E O'GradyUniversity of Maryland, College Park, College Park, MD, USA.
Robert P SchwartzFriends Research Institute, 1040 Park Avenue, Suite 103, Baltimore, MD, 21201, USA.
Friends Research Institute · USEmmes (United States) · USVirginia Commonwealth University · USDuke University · USNational Institute on Drug Abuse · USNew York University · USUniversity of Maryland, College Park · US

Funding

CLINICAL TRIALS NETWORK MID-ATLANTIC COLLABORATIVE GROUPU10DA013034 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SCHWARTZ, ROBERT P, STITZER, MAXINE L · 1999 to 2015
$25.2M
Clinical Trials Network: Mid-Atlantic Integrated Care Research CollaborativeUG1DA013034 · NIDA · JOHNS HOPKINS UNIVERSITY · PI BIGELOW, GEORGE, SCHWARTZ, ROBERT P · 2015 to 2019
$11.0M
Project-003UG1DA040317 · NIDA · DUKE UNIVERSITY · PI WU, LI-TZY · 2015 to 2019
$9.0M
NIDA NIH HHS U10 DA013034NIDA NIH HHS UG1 DA013034NIDA NIH HHS UG1 DA040317
6 · The paper itself

Abstract

backgroundThe Tobacco, Alcohol, Prescription Medication, and Other Substance use (TAPS) tool is a combined two-part screening and brief assessment developed for adult primary care patients. The tool's first-stage screening component (TAPS-1) consists of four items asking about past 12-month use for four substance categories, with response options of never, less than monthly, monthly, weekly, and daily or almost daily.

objectiveTo validate the TAPS-1 in primary care patients.

designParticipants completed the TAPS tool in self- and interviewer-administered formats, in random order. In this secondary analysis, the TAPS-1 was evaluated against DSM-5 substance use disorder (SUD) criteria to determine optimal cut-points for identifying unhealthy substance use at three severity levels (problem use, mild SUD, and moderate-to-severe SUD).

participantsTwo thousand adult patients at five primary care sites. MAIN MEASURES: DSM-5 SUD criteria were determined via the modified Composite International Diagnostic Interview. Oral fluid was used as a biomarker of recent drug use. KEY

resultsOptimal frequency-of-use cut-points on the self-administered TAPS-1 for identifying SUDs were ≥ monthly use for tobacco and alcohol (sensitivity = 0.92 and 0.71, specificity = 0.80 and 0.85, AUC = 0.86 and 0.78, respectively) and any reported use for illicit drugs and prescription medication misuse (sensitivity = 0.93 and 0.89, specificity = 0.85 and 0.91, AUC = 0.89 and 0.90, respectively). The performance of the interviewer-administered format was similar. When administered first, the self-administered format yielded higher disclosure rates for past 12-month alcohol use, illicit drug use, and prescription medication misuse. Frequency of use alone did not provide sufficient information to discriminate between gradations of substance use problem severity. Among those who denied drug use on the TAPS-1, less than 4% had a drug-positive biomarker.

conclusionsThe TAPS-1 can identify unhealthy substance use in primary care patients with a high level of accuracy, and may have utility in primary care for rapid triage.

Indexed as

AdultAlcohol DrinkingDisclosureDrug UsersFemaleHumansMass ScreeningPrimary Health CareSubstance-Related DisordersSurveys and QuestionnairesTobacco Productsprimary carescreeningsubstance use disordersunhealthy substance use

Identifiers

PMID28550609
PMCPMC5570743
OpenAlexW2618795138

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.